CSPC PHARMA releases 2025 Annual Report, AGM Circular and ESG Report

Bulletin Express04-28 19:43

On 29 April 2026, CSPC Pharmaceutical Group Limited (CSPC PHARMA) announced the official publication of its 2025 Annual Report, the accompanying AGM circular, notice of annual general meeting, proxy form, and the 2025 Environmental, Social and Governance (ESG) Report.

Both English and Chinese versions of these documents are now available on the company’s website (www.cspc.com.hk) as well as on the HKEX news portal (www.hkexnews.hk). Shareholders who previously elected to receive hard copies will find the printed materials enclosed with the notification.

Investors wishing to alter their future communication method—opting either for electronic access or printed copies—can submit the enclosed Change Request Form to the company’s registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. The completed form can be returned postage-free within Hong Kong.

Shareholders experiencing difficulties in accessing the electronic versions may request printed copies at no additional cost. Requests for a printed version of the ESG Report can also be made by written application to the registrar.

Further enquiries can be directed to the company hotline at (852) 2980 1333 during business hours. The notification was signed by Company Secretary Lo Tai On on behalf of CSPC PHARMA.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment